Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Women's health issues; WARM Act (H.R. 6743)
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Duration: January 1, 2012
to
present
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations , Law Enforcement/Crime/Criminal Justice , Foreign Relations , Pharmacy
Spending: about $2,240,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2012: U.S. Senate, House of Representatives, House of Representatives, Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 21.
Original Filing: 301569315.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Women's health issues; WARM Act (H.R. 6743)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 21.
Original Filing: 301534943.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Women's health issues; WARM Act (H.R. 6743)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 18, 2023.
Original Filing: 301505023.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 18, 2023.
Original Filing: 301478878.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 20, 2023.
Original Filing: 301461490.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Issues related to biopharmaceutical supply chain, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 18, 2023.
Original Filing: 301430272.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Issues related to biopharmaceutical supply chain, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415600.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Issues related to biopharmaceutical supply chain, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 19, 2022.
Original Filing: 301387169.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Issues related to biopharmaceutical supply chain, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 17, 2022.
Original Filing: 301357915.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Issues related to biopharmaceutical supply chain, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 20, 2022.
Original Filing: 301331550.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Issues related to biopharmaceutical supply chain, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Oct. 19, 2021.
Original Filing: 301304365.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Issues related to biopharmaceutical supply chain, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301286779.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Issues related to biopharmaceutical supply chain, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on April 19, 2021.
Original Filing: 301258242.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Issues related to biopharmaceutical supply chain, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301239322.xml
Lobbying Issues
Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP).
ASP, generally
Medicare Part D, including removal of safe harbor protection for drug rebates
Medicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program
Prescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B.
S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to lobbying disclosure for US affiliates
Agencies Lobbied
U.S. Senate
Lobbying Issues
House and Senate Appropriations for FY 2021
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
Roberti Global (fka Roberti White, LLC) amended a lobbying report for representation of Astellas Pharma US, Inc. in Q42020 on Jan. 20, 2021.
Original Filing: 301239399.xml
Lobbying Issues
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
House and Senate Appropriations for FY 2021
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to lobbying disclosure for US affiliates
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2020
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 19, 2020.
Original Filing: 301214492.xml
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to lobbying disclosure for US affiliates
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for FY 2021
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301201227.xml
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to lobbying disclosure for US affiliates
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for FY 2021
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301175480.xml
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to lobbying disclosure for US affiliates
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for FY ending Sept. 30, 2019
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
Roberti Global (fka Roberti White, LLC) amended a lobbying report for representation of Astellas Pharma US, Inc. in Q42019 on Jan. 22, 2020.
Original Filing: 301129788.xml
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to lobbying disclosure for US affiliates
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for FY ending Sept. 30, 2019
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301124767.xml
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to lobbying disclosure for US affiliates
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for FY ending Sept. 30, 2019
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
Roberti Global (fka Roberti White, LLC) amended a lobbying report for representation of Astellas Pharma US, Inc. in Q32019 on Jan. 22, 2020.
Original Filing: 301129787.xml
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to lobbying disclosure for US affiliates
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for FY ending Sept. 30, 2019
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078236.xml
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to lobbying disclosure for US affiliates
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for FY ending Sept. 30, 2019
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 22, 2019.
Original Filing: 301056196.xml
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, including non-interference, rebate policy issues
Issues related to drug pricing, value, and transparency, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to lobbying disclosure for US affiliates
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for FY ending Sept. 30, 2019
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on April 22, 2019.
Original Filing: 301038669.xml
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA)
Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to lobbying disclosure for US affiliates
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for FY ending Sept. 30, 2019
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Jan. 22, 2019.
Original Filing: 301015908.xml
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) (S. 2852/H.R. 6378)
Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
"Issues related to lobbying disclosure for US affiliates in the Disclosing Foreign Influence Act (H.R.4170/S. 2039) and Foreign Agents Registration Amendments Act (S. 2482)"
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2018
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 22, 2018.
Original Filing: 300997780.xml
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to the Bayh-Dole Act (Pub. L. 96-517)
Issues related to drug pricing and value, generally
Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) (S. 2852/H.R. 6378)
Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
"Issues related to lobbying disclosure for US affiliates in the Disclosing Foreign Influence Act (H.R.4170/S. 2039) and Foreign Agents Registration Amendments Act (S. 2482)"
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2018
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 20, 2018.
Original Filing: 300977116.xml
Lobbying Issues
- Issues related to the Bayh-Dole Act (Pub. L. 96-517)
- Issues related to drug pricing and value, generally
- Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to Medicare Part B (HOPPS), generally
- Issues related to Medicare Part D; the Bipartisan Budget Act (H.R. 1892); and the Consolidated Appropriations Act (H.R. 1625)
- Issues related to the repeal of the Independent Payment Advisory Board (IPAB); Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849/S. 260); Protecting Medicare from Executive Action Act of 2017 (S. 251)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to lobbying disclosure for US affiliates in the Disclosing Foreign Influence Act (H.R.4170/S. 2039) and Foreign Agents Registration Amendments Act (S. 2482)
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on April 20, 2018.
Original Filing: 300956948.xml
Lobbying Issues
- Issues related to the Bayh-Dole Act (Pub. L. 96-517)
- Issues related to drug pricing and value, generally
- Issues related to the importation of prescription medicines, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to Medicare Part B (HOPPS), generally
- Issues related to Medicare Part D; the Bipartisan Budget Act (H.R. 1892); and the Consolidated Appropriations Act (H.R. 1625)
- Issues related to the repeal of the Independent Payment Advisory Board (IPAB); Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849/S. 260); Protecting Medicare from Executive Action Act of 2017 (S. 251)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to lobbying disclosure for US affiliates in the Disclosing Foreign Influence Act (H.R.4170/S. 2039) and Foreign Agents Registration Amendments Act (S. 2482)
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Jan. 22, 2018.
Original Filing: 300933052.xml
Lobbying Issues
- Issues related to the Bayh-Dole Act (Pub. L. 96-517)
- Issues related to drug pricing and value
- Issues related to the importation of prescription medicines
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to Medicare Part B (HOPPS) and Part D
- Provisions related to repeal of the Independent Payment Advisory Board (IPAB)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 20, 2017.
Original Filing: 300914439.xml
Lobbying Issues
- FDA Reauthorization Act (H.R. 2430/S. 934)
- Issues related to the Bayh-Dole Act (Pub. L. 96-517)
- Issues related to drug pricing and value
- Issues related to the importation of prescription medicines
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to Medicare Part B (HOPPS) and Part D
- Provisions related to repeal of the Independent Payment Advisory Board (IPAB)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300894124.xml
Lobbying Issues
- FDA Reauthorization Act (H.R. 2430/S. 934)
- Issues related to the Bayh-Dole Act (Pub. L. 96-517)
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to Medicare Part B (HOPPS) and Part D
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on April 20, 2017.
Original Filing: 300876533.xml
Lobbying Issues
- Legislation repealing and replacing the Affordable Care Act, including the American Health Care Act (H.R. 1628)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA VI)
- Bayh-Dole Act/ march in authority
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856198.xml
Lobbying Issues
- The Federal, Food, Drug and Cosmetic Act
- The Food and Drug Administration Safety and Innovation Act (FDASIA)
- Bayh-Dole Act/ march in authority
Agencies Lobbied
U.S. Senate
Lobbying Issues
- CMMI Part B Drug Payment Demonstration Program
- General reimbursement issues
- H.R. 1178- Ensuring Equal Access to Treatments Act- all provisions
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300837684.xml
Lobbying Issues
- The Federal, Food, Drug and Cosmetic Act
- The Food and Drug Administration Safety and Innovation Act (FDASIA)
- Bayh-Dole Act/ march in authority
Agencies Lobbied
U.S. Senate
Lobbying Issues
- CMMI Part B Drug Payment Demonstration Program
- General reimbursement issues
- H.R. 1178- Ensuring Equal Access to Treatments Act- all provisions
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 20, 2016.
Original Filing: 300820229.xml
Lobbying Issues
Issues involving: The Federal, Food, Drug and Cosmetic Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
- Bayh-Dole Act/march in authority
Agencies Lobbied
U.S. Senate
Lobbying Issues
General reimbursement issues
H.R. 1178 - Ensuring Equal Access to Treatments Act - all provisions
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on April 20, 2016.
Original Filing: 300802931.xml
Lobbying Issues
Issues involving: The Federal, Food, Drug and Cosmetic Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
- Bayh-Dole Act/march in authority
Agencies Lobbied
U.S. Senate
Lobbying Issues
General reimbursement issues
H.R. 1178 - Ensuring Equal Access to Treatments Act - all provisions
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on Jan. 20, 2016.
Original Filing: 300784388.xml
Lobbying Issues
Issues involving: The Federal, Food, Drug and Cosmetic Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General reimbursement issues
H.R. 1178 - Ensuring Equal Access to Treatments Act - all provisions
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Roberti White, LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on Oct. 20, 2015.
Original Filing: 300760437.xml
Lobbying Issues
Issues involving: The Federal, Food, Drug and Cosmetic Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General reimbursement issues
H.R. 1178 - Ensuring Equal Access to Treatments Act - all provisions
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Roberti White, LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on July 20, 2015.
Original Filing: 300743878.xml
Lobbying Issues
Issues involving: The Federal, Food, Drug and Cosmetic Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General reimbursement issues
H.R. 1178 - Ensuring Equal Access to Treatments Act - all provisions
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Roberti White, LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on April 20, 2015.
Original Filing: 300723088.xml
Lobbying Issues
Issues involving: The Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General reimbursement issues
H.R. 1178 - Ensuring Equal Access to Treatments Act - all provisions
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Roberti White, LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on Jan. 20, 2015.
Original Filing: 300704551.xml
Lobbying Issues
General reimbursement issues
H.R. 4857/S.2980 Ensuring Equal Access to Treatments Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving: The Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, Roberti White, LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on Oct. 19, 2014.
Original Filing: 300682536.xml
Lobbying Issues
General reimbursement issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving:?The Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, Roberti White, LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on July 21, 2014.
Original Filing: 300669757.xml
Lobbying Issues
General reimbursement issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving:?The Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, Roberti White, LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on April 21, 2014.
Original Filing: 300648581.xml
Lobbying Issues
General reimbursement issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving:?The Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. Senate
4th Quarter, 2013
In Q4, Roberti White, LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on Jan. 21, 2014.
Original Filing: 300626808.xml
Lobbying Issues
Issues involving:?The Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General reimbursement issues
Agencies Lobbied
U.S. Senate
3rd Quarter, 2013
In Q3, Roberti White, LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on Oct. 21, 2013.
Original Filing: 300604595.xml
Lobbying Issues
Issues involving:?The Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. Senate
Lobbying Issues
General reimbursement issues
Agencies Lobbied
U.S. Senate
2nd Quarter, 2013
In Q2, Roberti White, LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on July 22, 2013.
Original Filing: 300586477.xml
Lobbying Issues
General reimbursement issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving:?The Federal, Food, Drug and Cosmetic Act?The Prescription Drug User Fee Act (PDUFA)?Patient Protection and Affordable Care Act?The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. Senate
1st Quarter, 2013
In Q1, Roberti White LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on April 22, 2013.
Original Filing: 300560178.xml
Lobbying Issues
General reimbursement issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving:
The Federal, Food, Drug and Cosmetic Act
The Prescription Drug User Fee Act (PDUFA)
Patient Protection and Affordable Care Act
The Food and Drug Administration Safety and Innovation Act (FDASIA)
Agencies Lobbied
U.S. Senate
4th Quarter, 2012
In Q4, Roberti White LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on Jan. 22, 2013.
Original Filing: 300542037.xml
Lobbying Issues
General reimbursement issues
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues involving:
The Federal, Food, Drug and Cosmetic Act
The Prescription Drug User Fee Act (PDUFA)
Generating Antibiotic Incentives Now (GAIN) Act
Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2012
In Q3, Roberti White LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on Oct. 22, 2012.
Original Filing: 300520742.xml
Lobbying Issues
General reimbursement issues
Agencies Lobbied
House of Representatives
Lobbying Issues
The Federal, Food, Drug and Cosmetic Act
The Prescription Drug User Fee Act (PDUFA)
Generating Antibiotic Incentives Now (GAIN) Act
Patient Protection and Affordable Care Act
FDA Safety & Innovation Act
Agencies Lobbied
House of Representatives
2nd Quarter, 2012
In Q2, Roberti White LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on July 20, 2012.
Original Filing: 300499458.xml
Lobbying Issues
The Federal, Food, Drug and Cosmetic Act
The Prescription Drug User Fee Act (PDUFA)
Generating Antibiotic Incentives Now (GAIN) Act
Patient Protection and Affordable Care Act
Agencies Lobbied
House of Representatives
Type of Issue
Medicare/Medicaid
1st Quarter, 2012
In Q1, Roberti White LLC lobbied for Astellas Pharma US, Inc. , earning $30,000. The report was filed on April 19, 2012.
Original Filing: 300467751.xml
Lobbying Issues
The Federal, Food, Drug and Cosmetic Act
The Prescription Drug User Fee Act (PDUFA)
Generating Antibiotic Incentives Now (GAIN) Act
Patient Protection and Affordable Care Act
Agencies Lobbied
House of Representatives
Type of Issue
Medicare/Medicaid
1st Quarter, 2012
Roberti White filed a lobbying registration on Jan. 19, 2012 to represent Astellas Pharma US, Inc., effective Jan. 1, 2012.
Original Filing: 300452913.xml
Issue(s) they said they’d lobby about: The Federal, Food, Drug and Cosmetic Act
The Prescription Drug User Fee Act (PDUFA)
Generating Antibiotic Incentives Now (GAIN) Act
Patient Protection and Affordable Care Act .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...